Stay updated on Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial

Sign up to get notified when there's something new on the Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change represents the addition of neoadjuvant and adjuvant immunotherapy with durvalumab to standard neoadjuvant chemotherapy and surgery in urothelial carcinoma, aiming to improve event-free survival.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:58.000Z thumbnail image
  7. Check
    21 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying requirements such as written informed consent, histologically proven urothelial cell carcinoma, and various health conditions. Previously, this section only indicated that no information was provided.
    Difference
    39%
    Check dated 2024-05-22T20:53:29.000Z thumbnail image
  8. Check
    43 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T21:58:29.000Z thumbnail image

Stay in the know with updates to Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab Plus Chemotherapy in Operable Urothelial Cancer Clinical Trial page.